BioPharma Resources

Drug Trial Radar · NCT03337724

A Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Participants With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer

A Double-Blind, Placebo-Controlled, Randomized Phase III Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Patients With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer

Last checked: Nov 19, 2026Latest source record: Mar 12, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 579 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

579

Actual

Start

Jan 6, 2018

Primary completion

Jan 4, 2023

Study completion Jan 4, 2023

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
Nov 9, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will evaluate the efficacy of ipatasertib + paclitaxel versus placebo + paclitaxel in participants with histologically confirmed, locally advanced or metastatic triple-negative breast cancer (TNBC) and in participants with locally advanced or metastatic hormone receptor positive (HR+)/ human epidermal growth factor receptor 2 negative (HER2-) breast adenocarcinoma who are not suitable for endocrine therapy.

Conditions

  • Breast Cancer

Interventions

  • IpatasertibDrug

    Ipatasertib, 400 milligrams (mg), administered orally once a day (QD) on Days 1-21 of each 28-day cycle until disease progression, intolerable toxicity, elective withdrawal from the study, or study completion or termination.

  • PaclitaxelDrug

    Paclitaxel, 80 mg/square meter (m\^2), administered intravenously (IV) on Days 1, 8, and 15 of each 28-day cycle until disease progression, intolerable toxicity, elective withdrawal from the study, or study completion or termination.

  • PlaceboDrug

    Matching placebo, administered orally QD on Days 1-21 of each 28-day cycle until disease progression, intolerable toxicity, elective withdrawal from the study, or study completion or termination.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Cohort A: Progression-Free Survival (PFS)Time frame: From randomization up to 27 months
  2. Cohort B: PFSTime frame: From randomization up to 24.4 months
  3. Cohort C: PFSTime frame: From enrollment up to 31 months

Locations

176 sites in 30 countries. Site status is shown where the registry gives one.

  • UCSD Moores Cancer Center

    La Jolla, California

  • USC Norris Cancer Center

    Los Angeles, California

  • USC Norris Cancer Center; USC Oncology Hematology Newport Beach

    Newport Beach, California

  • Kaiser Permanente - Oakland

    Oakland, California

  • Kaiser Permanente - Roseville

    Roseville, California

  • UC Davis; Comprehensive Cancer Center

    Sacramento, California

  • Kaiser Permanente Sacramento Medical Center

    Sacramento, California

  • Kaiser Permanente - San Francisco (2238 Geary)

    San Francisco, California

  • UCSF Comprehensive Cancer Ctr

    San Francisco, California

  • K. Permanente - San Jose

    San Jose, California

  • Kaiser Permanente - San Leandro

    San Leandro, California

  • K. Permanente - Santa Clara

    Santa Clara, California

  • Kaiser Permanente - South San Francisco

    South San Francisco, California

  • Kaiser Permanente - Vallejo

    Vallejo, California

  • K. Permanente - Walnut Creek

    Walnut Creek, California

  • Memorial Regional Hospital

    Hollywood, Florida

  • Mount Sinai Comprehensive Cancer Center

    Miami Beach, Florida

  • UF Health Cancer Center at Orlando Health

    Orlando, Florida

  • Memorial Hospital West

    Pembroke Pines, Florida

  • University of Maryland

    Baltimore, Maryland

  • Mercy Medical Center

    Baltimore, Maryland

  • Johns Hopkins Sidney Kimmel Comprehensive Cancer Center

    Baltimore, Maryland

  • Memorial Sloan Kettering Cancer Center at Westchester

    Harrison, New York

  • Memorial Sloan Kettering

    New York, New York

  • West Clinic

    Germantown, Tennessee

  • Texas Oncology, P.A.

    Dallas, Texas

  • UT Southwestern Medical Center; Simmons Comprehensive Cancer Center, Simmons Pharmacy

    Dallas, Texas

  • Oncology Consultants PA

    Houston, Texas

  • Fundación CENIT para la Investigación en Neurociencias

    Buenos Aires, Argentina

  • Hosp Provincial D. Centenarios; Oncology Dept

    Rosario, Argentina

  • Chris O'Brien Lifehouse

    Camperdown, New South Wales, Australia

  • Calvary Mater Newcastle; Medical Oncology

    Waratah, New South Wales, Australia

  • Westmead Hospital; Medical Oncology

    Wentworthville, New South Wales, Australia

  • Mater Hospital; Cancer Services

    South Brisbane, Queensland, Australia

  • Cabrini Medical Centre; Oncology

    Malvern, Victoria, Australia

  • Fiona Stanley Hospital; FSH Cancer Centre Clinical Trials Unit

    Bull Creek, Western Australia, Australia

  • Cliniques Universitaires St-Luc

    Brussels, Belgium

  • GHdC Site Notre Dame

    Charleroi, Belgium

  • UZ Leuven Gasthuisberg

    Leuven, Belgium

  • Santa Casa de Misericordia de Salvador

    Salvador, Estado de Bahia, Brazil

Showing 40 of 176 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.